US20190249127A1 - Fiber scaffolds for enhancing cell proliferation in cell culture - Google Patents

Fiber scaffolds for enhancing cell proliferation in cell culture Download PDF

Info

Publication number
US20190249127A1
US20190249127A1 US16/379,499 US201916379499A US2019249127A1 US 20190249127 A1 US20190249127 A1 US 20190249127A1 US 201916379499 A US201916379499 A US 201916379499A US 2019249127 A1 US2019249127 A1 US 2019249127A1
Authority
US
United States
Prior art keywords
fiber scaffold
polymer fibers
fiber
electrospun polymer
scaffold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US16/379,499
Other versions
US10941375B2 (en
Inventor
Jed Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NFS IP Holdings LLC
Original Assignee
Nanofiber Solutions LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanofiber Solutions LLC filed Critical Nanofiber Solutions LLC
Priority to US16/379,499 priority Critical patent/US10941375B2/en
Assigned to NANOFIBER SOLUTIONS, LLC reassignment NANOFIBER SOLUTIONS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JOHNSON, JED
Publication of US20190249127A1 publication Critical patent/US20190249127A1/en
Application granted granted Critical
Publication of US10941375B2 publication Critical patent/US10941375B2/en
Assigned to NFS IP HOLDINGS, LLC reassignment NFS IP HOLDINGS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NANOFIBER SOLUTIONS, LLC
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00Constructional details, e.g. recesses, hinges
    • C12M23/02Form or structure of the vessel
    • C12M23/14Bags
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068General culture methods using substrates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0667Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/003D culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/30Synthetic polymers

Definitions

  • the described invention relates in general to systems and devices for use in cell culture, and more specifically to a cell culture system and substrate that includes one or more polymer scaffolds adapted to be contained within a bioreactor, wherein the fiber scaffolds further include polymer fibers that have been created by electrospinning, and wherein the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.
  • mammalian cells require attachment to a substrate so that they may adequately proliferate and undergo normal cellular function.
  • These cells typically include a variety of stem or progenitor cells such as, for example, mesenchymal stem cells (MSC), and are of interest for a variety of clinical applications and therapies.
  • MSC mesenchymal stem cells
  • the number of viable cells required for a typical therapeutic dose can be millions or billions per patient.
  • stem cells easily differentiate into other undesirable cell types while being expanded in vitro, thereby reducing the efficiency of the expansion process and creating a major problem for stem cell suppliers. Accordingly, there is a significant need for commercially available technologies that are capable of greatly expanding a relatively small number of stem or progenitor cells into a much larger population of such cells while maintaining the pluripotency thereof.
  • a substrate for culturing cells includes at least one fiber scaffold adapted to be contained within a bioreactor.
  • the fiber scaffold further includes polymer fibers that have been created by electrospinning and the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.
  • a system for culturing cells includes at least one fiber scaffold adapted to be contained within a bioreactor, and a bioreactor.
  • the fiber scaffold further includes polymer fibers that have been created by electrospinning and the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.
  • the bioreactor may be disposable or permanent (i.e., reusable).
  • FIG. 1 is a photograph of exemplary polymer scaffolds of various shapes and sizes, in accordance with the present invention.
  • FIG. 2 is a photograph of exemplary polymer scaffolds of various shapes and sizes placed inside of a disposable bag bioreactor
  • FIG. 3 is a photograph of randomly oriented polymer fibers deposited onto the surface of a disposable bag bioreactor
  • FIG. 4 is a photograph of aligned polymer fibers deposited onto the surface of a disposable bag bioreactor
  • FIG. 5 is a photograph of dispersed or free-floating fibers in solution
  • FIG. 6 is a light microscope image of dispersed polymer fiber showing significantly more spacing between fibers than when in a consolidated mat or other structure;
  • FIG. 7 is a data graph illustrating the proliferation of human adipocyte-derived stem cells on different types of nanofibers, in accordance with the present invention.
  • FIG. 8 is a bar graph illustrating increased cell growth/expansion on the polymer fibers of the present invention.
  • FIGS. 9-12 are bar graphs presenting human induced pluripotent stem cell (iPSs) and embryonic stem cell (ECs) data;
  • FIGS. 13-14 are bar graphs that illustrate enhanced cell growth on nanofiber scaffolds made from a blend of PET and PU compared with plain PET and plain PU using human mesenchymal stem cells;
  • FIG. 15 is a photograph of a polymer fiber having a core/shell construction.
  • the process of electrospinning is driven by the application of a high voltage, typically between 0 and 30 kV, to a droplet of a polymer solution or melt at a flow rate between 0 and 50 ml/h to create a condition of charge separation between two electrodes and within the polymer solution to produce a polymer jet.
  • a typical polymer solution includes a polymer such as polycaprolactone, polystyrene, or polyethersulfone and a solvent such as 1,1,1,3,3,3-Hexafluoro-2-propanol, N,N-Dimethylformamide, acetone, or tetrahydrofuran in a concentration range of 1-50 wt %.
  • a high voltage typically between 0 and 30 kV
  • a polymer nanofiber precursor solution is prepared by dissolving 9 wt % polyethylene terephthalate (PET) (Indorama Ventures) in a mixture of nine parts 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) and one part trifluoroacetic acid.
  • PET polyethylene terephthalate
  • HFIP 1,1,1,3,3,3-hexafluoroisopropanol
  • trifluoroacetic acid 9 wt % polyethylene terephthalate
  • the solution is heated to 60° C. followed by continuous stirring to dissolve the PET.
  • the solution is cooled to room temperature and placed in a syringe (e.g., 60 cc) with a blunt tip needle (e.g., 20 gauge).
  • the nanofibers are formed by electrospinning using a high voltage DC power supply (Glassman High Voltage, Inc., High Bridge, N.J.) set to 1 kV-40 kV (e.g., +15 kV) positive or negative polarity, a 5-30 cm (e.g., 15 cm) tip-to-substrate distance, and a 1 ⁇ l/hr to 100 mL/hr (e.g., 10 ml/hr) flow rate. It is possible to use a needle array including a large number of needles (e.g., >1000) to increase system output.
  • the scaffold may be placed in a vacuum overnight and heated to ensure removal of residual solvent (typically less than 10 ppm) and treated using radio frequency gas plasma or corona for one second to one minute to make the fibers more hydrophilic and promote cell attachment thereto.
  • Suitable synthetic polymers include polycaprolactone (PCL), polyethylene terephthalate (PET), polystyrene (PS), polylactic acid (PLA), polyglycolic acid (PGA), polyurethane (PU), polyethersulfone, polyamide, Eudragit® (a polymerization of acrylic and methacrylic acids or their esters), polyetherketoneketone (PEKK), polyglycerol sebacate (PGS), polyhydroxybutyrate (PHB), trimethylene carbonate (TMC) and/or combinations thereof and/or derivatives thereof.
  • PCL polycaprolactone
  • PET polyethylene terephthalate
  • PS polystyrene
  • PLA polylactic acid
  • PGA polyglycolic acid
  • PU polyurethane
  • PES polyetherketoneketone
  • PES polyglycerol sebacate
  • PHS polyhydroxybutyrate
  • TMC trimethylene carbonate
  • Suitable natural polymers include gelatin, collagen, chitosan, fibrinogen, hyaluronic acid, cellulose, and/or combinations thereof and/or derivatives thereof.
  • Suitable solvents may include acetone, dimethylformamide, trifluoroacetic acid, hexafluoroisopropanol, acetic acid, dimethylacetamide, chloroform, dichloromethane, water, ionic compounds, or combinations thereof.
  • the polymer fibers of this invention may include non-resorbable materials such as polyethylene, terephthalate, silicone, polyurethane, polycarbonate, polyether-ketoneketone, polyethersulfone, polyamide, polystyrene, Eudragit®, polyethylene terephthalate, polypropylene, or combinations thereof. and/or resorbable materials such as polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), polyethylene terephthalate (PET) polypropylene (PP), or combinations thereof, and/or materials that may be preferentially dissolved by changes in pH, temperature or the addition of reagents to facilitate cell harvesting.
  • PCL polycaprolactone
  • PLA polylactic acid
  • PGA polyglycolic acid
  • PET polyethylene terephthalate
  • PP polypropylene
  • Eudragit® is a pH sensitive polymer and Poly(N-isopropylacrylamide) is a thermo-responsive polymer that facilitates cell release from the fibers.
  • the polymer fibers may be coated or otherwise treated with at least one compound that is operative to promote cellular attachment to the scaffold or to prohibit unwanted cell differentiation, and those compounds may include proteins, peptides, cytokines, small molecules (e.g., drugs) or combinations thereof.
  • the polymer fibers of this invention may also include a core/shell construction which may be coated with a compound that promotes cell release therefrom.
  • the fiber scaffolds of the present invention may be used with bioreactors of different sizes and shapes, as well as those that are disposable or permanent (i.e., reusable).
  • fiber scaffolds of various sizes, shapes, and porosities may be utilized (see FIGS. 1-2 ).
  • the polymer fibers in these scaffolds may be randomly arranged relative to one another or may be aligned with one another (see FIGS. 3-4 ).
  • the fiber scaffolds of this invention may be adhered to the bioreactor walls or other surfaces or may be dispersed, individual fibers that are free-floating in the cell culture media contained in a bioreactor (see FIGS.
  • These various fiber structures may be placed into the bioreactor at a manufacturing facility, sealed, sterilized, and then shipped to the customer. Alternately, these fiber structures may be sold separately and placed in the bioreactor by a person performing cell culture.
  • fiber is deposited directly onto the bag surface by placing a negatively charged substrate behind the bag or placing an anti-static bar behind the bag. This technique permits uniform deposition of the positively charged fibers onto the bag surface.
  • the fibers may be attached to the bioreactor walls with adhesives, heat, laser welding, ultrasonic welding, or other methods.
  • the fiber scaffold has been manufactured as a sheet of polymer fibers and then cut into pieces of at least one predetermined size prior to placement in the bioreactor. Cutting may be accomplished with scissors, a knife, or by tearing the polymer fiber sheet apart to form individual scaffolds of various sizes such as, for example, about 1 mm 3 fiber scaffolds to about 1 cm 3 fiber scaffolds.
  • a tissue homogenizer may be used to chop and shred polymer fiber sheets, which then allows the fibers to then be fully dispersed in liquid.
  • FIG. 7 is a data graph illustrating the proliferation of human adipose-derived stem cells (hADSCs) on different types of nanofibers.
  • hADSCs human adipose-derived stem cells
  • Multiple replicates of hADSCs were seeded in 24-well plates containing five different randomly oriented three-dimensional nanofiber matrices. Seven days after initial seeding, the cells were trypsinized and re-suspended in culture media. Cell enumeration and viability was determined by trypan blue exclusion.
  • Fold increases of hADSCs grown on three-dimensional nanofiber matrices relative to control cells grown on standard two-dimensional tissue culture polystyrene (TCPS) are quantified in FIG. 7 .
  • the data indicates that each three-dimensional nanofiber matrix supports the growth of hADSCs and results in a significant increase in expansion rates of cells compared to two dimensional TCPS.
  • FIG. 8 is a bar graph that illustrates increased cell growth/expansion on the polymer fibers of the present invention.
  • hMSCs human mesenchymal stem cells
  • FIGS. 9-12 are bar graphs presenting human induced pluripotent stem cell (iPSs) and embryonic stem cell (ECs) data. Embryonic stem cells typically need feeder cells or collagen on which to grow and the data in these Figures demonstrates nearly the same growth, but using a clean synthetic fiber scaffold. This feature of the present invention is important for cost reduction and translation to clinical therapies due to the superior control of the synthetic surface.
  • FIGS. 13-14 are bar graphs that illustrate enhanced cell growth on nanofiber scaffolds made from a blend of PET and PU compared with just PET and/or just PU using human MSCs.
  • FIG. 15 is a photograph of a polymer fiber that is compatible with the present invention, wherein the fiber has a core/shell construction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Clinical Laboratory Science (AREA)
  • Sustainable Development (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A substrate for culturing cells that includes at least one fiber scaffold adapted to be contained within a disposable or non-disposable bioreactor, wherein the fiber scaffold further includes polymer fibers that have been created by electrospinning, and wherein the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.

Description

    BACKGROUND OF THE INVENTION
  • The described invention relates in general to systems and devices for use in cell culture, and more specifically to a cell culture system and substrate that includes one or more polymer scaffolds adapted to be contained within a bioreactor, wherein the fiber scaffolds further include polymer fibers that have been created by electrospinning, and wherein the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.
  • Certain types of mammalian cells require attachment to a substrate so that they may adequately proliferate and undergo normal cellular function. These cells typically include a variety of stem or progenitor cells such as, for example, mesenchymal stem cells (MSC), and are of interest for a variety of clinical applications and therapies. However, the number of viable cells required for a typical therapeutic dose can be millions or billions per patient. Additionally, stem cells easily differentiate into other undesirable cell types while being expanded in vitro, thereby reducing the efficiency of the expansion process and creating a major problem for stem cell suppliers. Accordingly, there is a significant need for commercially available technologies that are capable of greatly expanding a relatively small number of stem or progenitor cells into a much larger population of such cells while maintaining the pluripotency thereof.
  • Current commercially used cell expansion processes typically involve large reusable stainless steel or glass bioreactors that must be cleaned and disinfected between batches or disposable, single-use bioreactors that resemble plastic bags. Stem cells are added to these bioreactors with appropriate media and reagents for promoting cell growth and then the bioreactors are closely monitored until a desired concentration of cells is achieved. For adherent cells, porous beads made from polystyrene and other polymers are added into the growth media and cell mixture to allow the cells to attach and grow normally. However, once the desired concentration of cells is achieved it is very difficult to remove all of the cells from the porous beads. This results in a low efficiency of usable cells for the desired end application. Therefore, there is an ongoing need for a cell culture system that permits desired cell growth and proliferation and that allows cultured cells to be harvested efficiently and in large numbers.
  • SUMMARY OF THE INVENTION
  • The following provides a summary of certain exemplary embodiments of the present invention. This summary is not an extensive overview and is not intended to identify key or critical aspects or elements of the present invention or to delineate its scope.
  • In accordance with one aspect of the present invention, a substrate for culturing cells is provided. This substrate includes at least one fiber scaffold adapted to be contained within a bioreactor. The fiber scaffold further includes polymer fibers that have been created by electrospinning and the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both.
  • In accordance with another aspect of the present invention, a system for culturing cells is provided. This system includes at least one fiber scaffold adapted to be contained within a bioreactor, and a bioreactor. The fiber scaffold further includes polymer fibers that have been created by electrospinning and the orientation of the fibers in the scaffold relative to one another is generally parallel, random, or both. The bioreactor may be disposable or permanent (i.e., reusable).
  • Additional features and aspects of the present invention will become apparent to those of ordinary skill in the art upon reading and understanding the following detailed description of the exemplary embodiments. As will be appreciated by the skilled artisan, further embodiments of the invention are possible without departing from the scope and spirit of the invention. Accordingly, the drawings and associated descriptions are to be regarded as illustrative and not restrictive in nature.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The accompanying Figures, which are incorporated into and form a part of the specification, illustrate one or more exemplary embodiments of the invention and, together with the general description given above and detailed description given below, serve to explain the principles of the invention, and wherein:
  • FIG. 1 is a photograph of exemplary polymer scaffolds of various shapes and sizes, in accordance with the present invention;
  • FIG. 2 is a photograph of exemplary polymer scaffolds of various shapes and sizes placed inside of a disposable bag bioreactor;
  • FIG. 3 is a photograph of randomly oriented polymer fibers deposited onto the surface of a disposable bag bioreactor;
  • FIG. 4 is a photograph of aligned polymer fibers deposited onto the surface of a disposable bag bioreactor;
  • FIG. 5 is a photograph of dispersed or free-floating fibers in solution;
  • FIG. 6 is a light microscope image of dispersed polymer fiber showing significantly more spacing between fibers than when in a consolidated mat or other structure;
  • FIG. 7 is a data graph illustrating the proliferation of human adipocyte-derived stem cells on different types of nanofibers, in accordance with the present invention;
  • FIG. 8 is a bar graph illustrating increased cell growth/expansion on the polymer fibers of the present invention;
  • FIGS. 9-12 are bar graphs presenting human induced pluripotent stem cell (iPSs) and embryonic stem cell (ECs) data;
  • FIGS. 13-14 are bar graphs that illustrate enhanced cell growth on nanofiber scaffolds made from a blend of PET and PU compared with plain PET and plain PU using human mesenchymal stem cells; and
  • FIG. 15 is a photograph of a polymer fiber having a core/shell construction.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Exemplary embodiments of the present invention are now described with reference to the Figures. Although the following detailed description contains many specifics for the purposes of illustration, a person of ordinary skill in the art will appreciate that many variations and alterations to the following details are within the scope of the invention. Accordingly, the following embodiments of the invention are set forth without any loss of generality to, and without imposing limitations upon, the claimed invention. With general reference to FIGS. 1-15, one or more specific embodiments of this invention shall now be described in greater detail.
  • In accordance with this invention, the process of electrospinning is driven by the application of a high voltage, typically between 0 and 30 kV, to a droplet of a polymer solution or melt at a flow rate between 0 and 50 ml/h to create a condition of charge separation between two electrodes and within the polymer solution to produce a polymer jet. A typical polymer solution includes a polymer such as polycaprolactone, polystyrene, or polyethersulfone and a solvent such as 1,1,1,3,3,3-Hexafluoro-2-propanol, N,N-Dimethylformamide, acetone, or tetrahydrofuran in a concentration range of 1-50 wt %. As the jet of polymer solution travels toward the electrode it is elongated into small diameter fibers typically in the range of 0.1-30 μm.
  • In preparing an exemplary scaffold, a polymer nanofiber precursor solution is prepared by dissolving 9 wt % polyethylene terephthalate (PET) (Indorama Ventures) in a mixture of nine parts 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) and one part trifluoroacetic acid. The solution is heated to 60° C. followed by continuous stirring to dissolve the PET. The solution is cooled to room temperature and placed in a syringe (e.g., 60 cc) with a blunt tip needle (e.g., 20 gauge). The nanofibers are formed by electrospinning using a high voltage DC power supply (Glassman High Voltage, Inc., High Bridge, N.J.) set to 1 kV-40 kV (e.g., +15 kV) positive or negative polarity, a 5-30 cm (e.g., 15 cm) tip-to-substrate distance, and a 1 μl/hr to 100 mL/hr (e.g., 10 ml/hr) flow rate. It is possible to use a needle array including a large number of needles (e.g., >1000) to increase system output. The scaffold may be placed in a vacuum overnight and heated to ensure removal of residual solvent (typically less than 10 ppm) and treated using radio frequency gas plasma or corona for one second to one minute to make the fibers more hydrophilic and promote cell attachment thereto.
  • In accordance with this invention, it is possible to produce nanometer or micrometer sized fibers from a variety of synthetic and natural polymers. Suitable synthetic polymers include polycaprolactone (PCL), polyethylene terephthalate (PET), polystyrene (PS), polylactic acid (PLA), polyglycolic acid (PGA), polyurethane (PU), polyethersulfone, polyamide, Eudragit® (a polymerization of acrylic and methacrylic acids or their esters), polyetherketoneketone (PEKK), polyglycerol sebacate (PGS), polyhydroxybutyrate (PHB), trimethylene carbonate (TMC) and/or combinations thereof and/or derivatives thereof. Suitable natural polymers include gelatin, collagen, chitosan, fibrinogen, hyaluronic acid, cellulose, and/or combinations thereof and/or derivatives thereof. Suitable solvents may include acetone, dimethylformamide, trifluoroacetic acid, hexafluoroisopropanol, acetic acid, dimethylacetamide, chloroform, dichloromethane, water, ionic compounds, or combinations thereof. By predetermining the optimum fiber material and fiber diameter for each cell type or application, higher rates of cellular expansion, while maintaining a larger percentage of pluripotent cells, can be achieved as compared to other technologies.
  • The polymer fibers of this invention may include non-resorbable materials such as polyethylene, terephthalate, silicone, polyurethane, polycarbonate, polyether-ketoneketone, polyethersulfone, polyamide, polystyrene, Eudragit®, polyethylene terephthalate, polypropylene, or combinations thereof. and/or resorbable materials such as polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), polyethylene terephthalate (PET) polypropylene (PP), or combinations thereof, and/or materials that may be preferentially dissolved by changes in pH, temperature or the addition of reagents to facilitate cell harvesting. Eudragit® is a pH sensitive polymer and Poly(N-isopropylacrylamide) is a thermo-responsive polymer that facilitates cell release from the fibers. The polymer fibers may be coated or otherwise treated with at least one compound that is operative to promote cellular attachment to the scaffold or to prohibit unwanted cell differentiation, and those compounds may include proteins, peptides, cytokines, small molecules (e.g., drugs) or combinations thereof. The polymer fibers of this invention may also include a core/shell construction which may be coated with a compound that promotes cell release therefrom.
  • The fiber scaffolds of the present invention may be used with bioreactors of different sizes and shapes, as well as those that are disposable or permanent (i.e., reusable). For the purpose of incorporating the fiber scaffolds of this invention into such bioreactors while still facilitating easy cell removal, fiber scaffolds of various sizes, shapes, and porosities may be utilized (see FIGS. 1-2). The polymer fibers in these scaffolds may be randomly arranged relative to one another or may be aligned with one another (see FIGS. 3-4). Depending on bioreactor geometry, the fiber scaffolds of this invention may be adhered to the bioreactor walls or other surfaces or may be dispersed, individual fibers that are free-floating in the cell culture media contained in a bioreactor (see FIGS. 5-6). These various fiber structures may be placed into the bioreactor at a manufacturing facility, sealed, sterilized, and then shipped to the customer. Alternately, these fiber structures may be sold separately and placed in the bioreactor by a person performing cell culture. To adhere polymer fiber to bioreactor bags, fiber is deposited directly onto the bag surface by placing a negatively charged substrate behind the bag or placing an anti-static bar behind the bag. This technique permits uniform deposition of the positively charged fibers onto the bag surface. Alternatively, the fibers may be attached to the bioreactor walls with adhesives, heat, laser welding, ultrasonic welding, or other methods.
  • In some embodiments of this invention, the fiber scaffold has been manufactured as a sheet of polymer fibers and then cut into pieces of at least one predetermined size prior to placement in the bioreactor. Cutting may be accomplished with scissors, a knife, or by tearing the polymer fiber sheet apart to form individual scaffolds of various sizes such as, for example, about 1 mm3 fiber scaffolds to about 1 cm3 fiber scaffolds. For embodiments that utilize dispersed fibers, a tissue homogenizer may be used to chop and shred polymer fiber sheets, which then allows the fibers to then be fully dispersed in liquid.
  • FIG. 7 is a data graph illustrating the proliferation of human adipose-derived stem cells (hADSCs) on different types of nanofibers. Multiple replicates of hADSCs were seeded in 24-well plates containing five different randomly oriented three-dimensional nanofiber matrices. Seven days after initial seeding, the cells were trypsinized and re-suspended in culture media. Cell enumeration and viability was determined by trypan blue exclusion. Fold increases of hADSCs grown on three-dimensional nanofiber matrices relative to control cells grown on standard two-dimensional tissue culture polystyrene (TCPS) are quantified in FIG. 7. The data indicates that each three-dimensional nanofiber matrix supports the growth of hADSCs and results in a significant increase in expansion rates of cells compared to two dimensional TCPS.
  • FIG. 8 is a bar graph that illustrates increased cell growth/expansion on the polymer fibers of the present invention. With regard to the data appearing in FIG. 8, multiple replicates of human mesenchymal stem cells (hMSCs) were seeded in 24-well plates containing five different randomly oriented three-dimensional fiber matrices. Seven days after initial seeding, cells were trypsinized and resuspended in culture media. Cell enumeration and viability was determined by trypan blue exclusion. Fold increases of hMSCs grown on three dimensional matrices relative to control cells grown on standard 2D tissue culture polystyrene (TCPS) are shown in FIG. 8. The data indicate that each three-dimensional fiber matrix supports the growth of hMSCs and demonstrates a significant increase in the expansion rates of cells cultured in three dimensions compared to two dimensional TCPS.
  • FIGS. 9-12 are bar graphs presenting human induced pluripotent stem cell (iPSs) and embryonic stem cell (ECs) data. Embryonic stem cells typically need feeder cells or collagen on which to grow and the data in these Figures demonstrates nearly the same growth, but using a clean synthetic fiber scaffold. This feature of the present invention is important for cost reduction and translation to clinical therapies due to the superior control of the synthetic surface. FIGS. 13-14 are bar graphs that illustrate enhanced cell growth on nanofiber scaffolds made from a blend of PET and PU compared with just PET and/or just PU using human MSCs. FIG. 15 is a photograph of a polymer fiber that is compatible with the present invention, wherein the fiber has a core/shell construction.
  • While the present invention has been illustrated by the description of exemplary embodiments thereof, and while the embodiments have been described in certain detail, it is not the intention of the Applicant to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages and modifications will readily appear to those skilled in the art. Therefore, the invention in its broader aspects is not limited to any of the specific details, representative devices and methods, and/or illustrative examples shown and described. Accordingly, departures may be made from such details without departing from the spirit or scope of the applicant's general inventive concept.

Claims (15)

1.-27. (canceled)
28. A fiber scaffold comprising electrospun polymer fibers, wherein each electrospun polymer fiber includes a blend of polyethylene terephthalate and polyurethane, the blend having a weight ratio of about 2:8 polyethylene terephthalate to polyurethane.
29. The fiber scaffold of claim 28, wherein the electrospun polymer fibers have an orientation relative to one another that is generally parallel, random, or a combination thereof.
30. The fiber scaffold of claim 28, wherein the electrospun polymer fibers have a diameter in the range of 0.1-30 μm.
31. The fiber scaffold of claim 28, formed into a sheet.
32. The fiber scaffold of claim 28, wherein the electrospun polymer fibers further comprise a treatment configured to promote cellular attachment to the fiber scaffold.
33. The fiber scaffold of claim 32, wherein the treatment is selected from the group consisting of proteins, peptides, cytokines, small molecules, and combinations thereof.
34. The fiber scaffold of claim 28, further comprising electrospun polymer fibers that include a synthetic polymer selected from the group consisting of polycaprolactone, polystyrene, polylactic acid, polyglycolic acid, polyethersulfone, polyamide, polyetherketoneketone, a polymerization of acrylic and methacrylic acids or their esters, polyglycerol sebacate, polyhydroxybutyrate, trimethyl carbonate, combinations thereof, and derivatives thereof.
35. The fiber scaffold of claim 28, further comprising electrospun polymer fibers that include a natural polymer selected from the group consisting of gelatin, collagen, fibrinogen, hyaluronic acid, cellulose, combinations thereof, and derivatives thereof.
36. The fiber scaffold of claim 28, further comprising electrospun polymer fibers that include a non-resorbable material selected from the group consisting of polyethylene, terephthalate, silicone, polycarbonate, polyether-ketoneketone, polyethersulfone, polyamide, polystyrene, a polymerization of acrylic and methacrylic acids or their esters, polypropylene, and combinations thereof.
37. The fiber scaffold of claim 28, further comprising electrospun polymer fibers that include a resorbable material selected from the group consisting of polycaprolactone, polylactic acid, polyglycolic acid, polyhydroxybutyrate, trimethylene carbonate, and combinations thereof.
38. The fiber scaffold of claim 28, wherein the electrospun polymer fibers further comprise a material that may be dissolved by one or more of a changing pH, a changing temperature, and an addition of reagents that facilitate the harvesting of cells from the fibers.
39. The fiber scaffold of claim 28, wherein the electrospun polymer fibers have a core/shell construction.
40. A system for culturing cells, the system comprising the scaffold of claim 28.
41. The system of claim 40, further comprising a bioreactor.
US16/379,499 2012-08-21 2019-04-09 Fiber scaffolds for enhancing cell proliferation in cell culture Active 2033-12-30 US10941375B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/379,499 US10941375B2 (en) 2012-08-21 2019-04-09 Fiber scaffolds for enhancing cell proliferation in cell culture

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691611P 2012-08-21 2012-08-21
US13/971,154 US10294449B2 (en) 2012-08-21 2013-08-20 Fiber scaffolds for enhancing cell proliferation in cell culture
US16/379,499 US10941375B2 (en) 2012-08-21 2019-04-09 Fiber scaffolds for enhancing cell proliferation in cell culture

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/971,154 Continuation US10294449B2 (en) 2012-08-21 2013-08-20 Fiber scaffolds for enhancing cell proliferation in cell culture

Publications (2)

Publication Number Publication Date
US20190249127A1 true US20190249127A1 (en) 2019-08-15
US10941375B2 US10941375B2 (en) 2021-03-09

Family

ID=52480718

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/971,154 Active US10294449B2 (en) 2012-08-21 2013-08-20 Fiber scaffolds for enhancing cell proliferation in cell culture
US16/379,499 Active 2033-12-30 US10941375B2 (en) 2012-08-21 2019-04-09 Fiber scaffolds for enhancing cell proliferation in cell culture

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/971,154 Active US10294449B2 (en) 2012-08-21 2013-08-20 Fiber scaffolds for enhancing cell proliferation in cell culture

Country Status (1)

Country Link
US (2) US10294449B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562225B2 (en) 2011-11-21 2020-02-18 Nanofiber Solutions, Llc System for manufacturing fiber scaffolds for use in tracheal prostheses
US10588734B2 (en) 2010-06-17 2020-03-17 Washington University Biomedical patches with aligned fibers
US10632228B2 (en) 2016-05-12 2020-04-28 Acera Surgical, Inc. Tissue substitute materials and methods for tissue repair
US10653635B2 (en) 2012-01-12 2020-05-19 Nanofiber Solutions, Llc Nanofiber scaffolds for biological structures
US10682444B2 (en) 2012-09-21 2020-06-16 Washington University Biomedical patches with spatially arranged fibers
US10898608B2 (en) 2017-02-02 2021-01-26 Nanofiber Solutions, Llc Methods of improving bone-soft tissue healing using electrospun fibers
US11246959B2 (en) 2013-03-15 2022-02-15 Nanofiber Solutions, Llc Biocompatible fiber textiles for implantation

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689853B (en) 2016-08-27 2022-08-23 三维生物科技有限公司 Bioreactor
JP7371929B2 (en) * 2018-05-16 2023-10-31 株式会社幹細胞&デバイス研究所 cell scaffolding material
KR102332822B1 (en) * 2018-11-14 2021-11-30 주식회사 아모그린텍 Cell culture device
CN116694565A (en) * 2023-05-29 2023-09-05 广州启源生物医药有限公司 Method for amplifying mesenchymal stem cells

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218178B1 (en) 1998-05-08 2001-04-17 Flexcell International Corporation Loading station assembly
US6472202B1 (en) 1998-05-08 2002-10-29 Flexcell International Corporation Loading station assembly and method for tissue engineering
US20020090725A1 (en) 2000-11-17 2002-07-11 Simpson David G. Electroprocessed collagen
US6592623B1 (en) 1999-08-31 2003-07-15 Virginia Commonwealth University Intellectual Property Foundation Engineered muscle
US7615373B2 (en) 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
DE60128972T2 (en) 2000-04-19 2008-02-14 Corning Inc. Method for producing a multi-hole plate
US7029838B2 (en) 2001-03-30 2006-04-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Prevascularized contructs for implantation to provide blood perfusion
US6685956B2 (en) 2001-05-16 2004-02-03 The Research Foundation At State University Of New York Biodegradable and/or bioabsorbable fibrous articles and methods for using the articles for medical applications
US7384742B2 (en) 2002-08-16 2008-06-10 Decision Biomarkers, Inc. Substrates for isolating reacting and microscopically analyzing materials
CA2596957C (en) 2004-12-03 2015-04-14 New Jersey Institute Of Technology Substrate recognition by differentiable human mesenchymal stem cells
WO2006099332A2 (en) 2005-03-11 2006-09-21 Wake Forest University Health Sciences Production of tissue engineered digits and limbs
EP1868660B1 (en) 2005-04-04 2016-08-03 Technion Research & Development Foundation Limited Medical scaffold, methods of fabrication and using thereof
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US8202551B2 (en) 2005-06-15 2012-06-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Tissue engineered cartilage, method of making same, therapeutic and cosmetic surgical applications using same
US20080025930A1 (en) 2006-07-31 2008-01-31 Hugo Corstjens Anti-aging Compositions Comprising Menyanthes Trifoliata Leaf Extracts and Methods of Use Thereof
US8361502B2 (en) * 2006-10-18 2013-01-29 The Johns Hopkins University Compositions and methods for the expansion and differentiation of stem cells
WO2008137659A1 (en) 2007-05-04 2008-11-13 University Of Virginia Patent Foundation Compositions and methods for making and using laminin nanofibers
WO2009089035A1 (en) 2008-01-10 2009-07-16 Arteriocyte Inc. Methods and systems for expanding ac133+ cells and directing differentiation
US20110287082A1 (en) 2008-01-25 2011-11-24 Jennifer Margaret Smith Multilayer Scaffold
US8691274B2 (en) 2008-02-14 2014-04-08 Wake Forest University Health Sciences Inkjet printing of tissues and cells
NL1036038C (en) 2008-10-09 2010-04-14 Univ Eindhoven Tech Multilayer preform obtained by electro-spinning, method for producing a preform as well as use thereof.
US9476026B2 (en) 2009-03-12 2016-10-25 New Jersey Institute Of Technology Method of tissue repair using a piezoelectric scaffold
US9771557B2 (en) 2009-03-12 2017-09-26 New Jersey Institute Of Technology Piezoelectric scaffold for nerve growth and repair
US9334476B2 (en) 2009-03-12 2016-05-10 New Jersey Institute Of Technology Method for nerve growth and repair using a piezoelectric scaffold
WO2010124207A1 (en) * 2009-04-24 2010-10-28 The Ohio State University Interactive microenvironment system
AU2011251055B2 (en) * 2010-05-12 2014-12-04 Scinus Cell Expansion B.V. Cell - culture - bag
US9861465B2 (en) 2010-09-22 2018-01-09 Nanyang Technological University Method for forming a tissue construct and use thereof
WO2012078472A2 (en) 2010-12-05 2012-06-14 Nanonerve, Inc. Fibrous polymer scaffolds having diametrically patterned polymer fibers
GB201021438D0 (en) 2010-12-16 2011-02-02 Imp Innovations Ltd Layered fibrous construct
JP2013031595A (en) 2011-08-03 2013-02-14 Kyoto Institute Of Technology Tubular body and method for manufacturing the same
US9597425B2 (en) 2011-10-18 2017-03-21 St. Teresa Medical, Inc. Method of forming a hemostatic product
WO2013078051A1 (en) 2011-11-21 2013-05-30 Johnson Jed K Fiber scaffolds for use in tracheal prostheses
US9345810B2 (en) 2012-02-07 2016-05-24 Lifenet Health Liquefaction of bone matrix
US9877822B2 (en) 2012-04-24 2018-01-30 Biostage, Inc. Engineered tissue scaffolds and supports therefor
EP2846849A1 (en) 2012-05-10 2015-03-18 The Trustees Of The Stevens Institute Of Technology Biphasic osteochondral scaffold for reconstruction of articular cartilage
WO2014031721A1 (en) 2012-08-21 2014-02-27 Johnson Jed K Fiber scaffolds for enhancing cell proliferation in cell culture
CN102908677A (en) 2012-11-09 2013-02-06 无锡中科光远生物材料有限公司 Preparation method of anti-adhesion absorbable hernia patch
US20140193374A1 (en) * 2012-12-07 2014-07-10 Arteriocyte Inc. Methods and compositions for culturing cells
WO2014160002A1 (en) 2013-03-14 2014-10-02 Lifenet Health Electrospinning apparatus and methods of use thereof
WO2014152906A2 (en) 2013-03-14 2014-09-25 Research Institute At Nationwide Children's Hospital, Inc. Tissue engineered intestine
US10195044B2 (en) 2013-07-12 2019-02-05 Sinai Health System Intervertebral disc implant

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311366B2 (en) 2010-06-17 2022-04-26 Washington University Biomedical patches with aligned fibers
US11471260B2 (en) 2010-06-17 2022-10-18 Washington University Biomedical patches with aligned fibers
US11096772B1 (en) 2010-06-17 2021-08-24 Washington University Biomedical patches with aligned fibers
US10588734B2 (en) 2010-06-17 2020-03-17 Washington University Biomedical patches with aligned fibers
US10617512B2 (en) 2010-06-17 2020-04-14 Washington University Biomedical patches with aligned fibers
US11071617B2 (en) 2010-06-17 2021-07-27 Washington University Biomedical patches with aligned fibers
US10888409B2 (en) 2010-06-17 2021-01-12 Washington University Biomedical patches with aligned fibers
US11000358B2 (en) 2010-06-17 2021-05-11 Washington University Biomedical patches with aligned fibers
US10562225B2 (en) 2011-11-21 2020-02-18 Nanofiber Solutions, Llc System for manufacturing fiber scaffolds for use in tracheal prostheses
US10653635B2 (en) 2012-01-12 2020-05-19 Nanofiber Solutions, Llc Nanofiber scaffolds for biological structures
US11737990B2 (en) 2012-01-12 2023-08-29 Nfs Ip Holdings, Llc Nanofiber scaffolds for biological structures
US11173234B2 (en) 2012-09-21 2021-11-16 Washington University Biomedical patches with spatially arranged fibers
US11253635B2 (en) 2012-09-21 2022-02-22 Washington University Three dimensional electrospun biomedical patch for facilitating tissue repair
US11596717B2 (en) 2012-09-21 2023-03-07 Washington University Three dimensional electrospun biomedical patch for facilitating tissue repair
US10682444B2 (en) 2012-09-21 2020-06-16 Washington University Biomedical patches with spatially arranged fibers
US11246959B2 (en) 2013-03-15 2022-02-15 Nanofiber Solutions, Llc Biocompatible fiber textiles for implantation
US10632228B2 (en) 2016-05-12 2020-04-28 Acera Surgical, Inc. Tissue substitute materials and methods for tissue repair
US11224677B2 (en) 2016-05-12 2022-01-18 Acera Surgical, Inc. Tissue substitute materials and methods for tissue repair
US11826487B2 (en) 2016-05-12 2023-11-28 Acera Surgical, Inc. Tissue substitute materials and methods for tissue repair
US10898608B2 (en) 2017-02-02 2021-01-26 Nanofiber Solutions, Llc Methods of improving bone-soft tissue healing using electrospun fibers
US11806440B2 (en) 2017-02-02 2023-11-07 Nfs Ip Holdings, Llc Methods of improving bone-soft tissue healing using electrospun fibers

Also Published As

Publication number Publication date
US10941375B2 (en) 2021-03-09
US10294449B2 (en) 2019-05-21
US20150056703A1 (en) 2015-02-26
US20160152954A9 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
US10941375B2 (en) Fiber scaffolds for enhancing cell proliferation in cell culture
WO2014031721A1 (en) Fiber scaffolds for enhancing cell proliferation in cell culture
US11737990B2 (en) Nanofiber scaffolds for biological structures
DK2739720T3 (en) Devices and methods for growing cells
EP2971318B1 (en) Biocompatible fiber textiles for implantation
Park et al. Creation of a hybrid scaffold with dual configuration of aligned and random electrospun fibers
US20210189329A1 (en) Production of extracellular vesicles from stem cells
Nguyen et al. Identification of sagging in melt-electrospinning of microfiber scaffolds
Lü et al. The effects of PHBV electrospun fibers with different diameters and orientations on growth behavior of bone-marrow-derived mesenchymal stem cells
US20140193374A1 (en) Methods and compositions for culturing cells
Xia et al. Oriented growth of rat Schwann cells on aligned electrospun poly (methyl methacrylate) nanofibers
Morelli et al. Microtube array membrane bioreactor promotes neuronal differentiation and orientation
Kannarkat et al. Embedding of magnetic nanoparticles in polycaprolactone nanofiber scaffolds to facilitate bone healing and regeneration
Wang et al. Biomimetic three‐dimensional anisotropic geometries by uniaxial stretching of poly (ε‐caprolactone) films: Degradation and mesenchymal stem cell responses
Bettahalli et al. Development of multilayer constructs for tissue engineering
Fromager et al. Recent Advances in Electrospun Fibers for Biological Applications
JP2015223111A (en) Methods and apparatuses for long term perfusion of high density cell culture
Selvam et al. Microporous poly (L-lactic acid) membranes fabricated by polyethylene glycol solvent-cast/particulate leaching technique
Ko et al. Surface modification of PHBV nanofiber mats for rapid cell cultivation and harvesting
Jafar et al. Plasma-Treated Electrospun PLGA Nanofiber Scaffold Supports Limbal Stem Cells
EP3795673A1 (en) Cell scaffold material
Zheng et al. Liquid Crystal Modified Polylactic Acid Improves Cytocompatibility and M2 Polarization of Macrophages to Promote Osteogenesis
Gonçalves et al. Potential of Electrospun Fibrous Scaffolds for Intestinal, Skin, and Lung Epithelial Tissue Modeling
Zhang et al. Polyurethane/Liquid Crystal Microfibers with pDNA Polyplex Loadings for the Optimal Release and Promotion of HUVEC Proliferation
Moon et al. A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

AS Assignment

Owner name: NANOFIBER SOLUTIONS, LLC, OHIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JOHNSON, JED;REEL/FRAME:049162/0572

Effective date: 20190422

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: NFS IP HOLDINGS, LLC, OHIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NANOFIBER SOLUTIONS, LLC;REEL/FRAME:061882/0663

Effective date: 20221024